Guardant Health (NASDAQ: GH) Smashes Q1 Estimates, Raises Guidance on Screening Growth

Guardant Health Inc. (NASDAQ: GH) demolished first-quarter estimates and raised full-year guidance after reporting explosive growth in liquid biopsy screening revenues, powered by FDA validation and widening adoption of its Guardant360 CDx companion diagnostic platform.

By the Numbers

• Revenue growth: 39.4% year-over-year, reflecting exceptional demand for cancer screening diagnostics
• Gross margin: 64.46%, strong for a molecular diagnostics provider
• Operating margin: -42.91%, reflecting heavy R&D and commercialization investments
• Full-year guidance: Raised, signaling management confidence in accelerating screening adoption

What Drove the Results

Guardant Health's 39.4% revenue explosion was driven by surging adoption of plasma-based cancer screening tests, which are gaining traction as insurers expand coverage and physicians integrate liquid biopsy into standard care protocols. The April FDA approval of Guardant360 CDx as a companion diagnostic for Arvinas and Pfizer's Veppanu (vepdegestrant) in ER+/HER2- breast cancer with ESR1 mutations adds a major revenue stream, as companion diagnostics carry higher margins and guaranteed patient throughput tied to therapeutic adoption.

The -42.91% operating margin reflects the company's aggressive investment phase. R&D spending is elevated as Guardant expands its test menu for early-stage cancers, and commercialization costs remain substantial as the company builds out its sales force to capture market share in the rapidly expanding liquid biopsy segment. This is typical for high-growth diagnostics firms transitioning from niche to mainstream markets.

The full-year guidance raise validates management's thesis that screening adoption is accelerating faster than expected, driven by clinical validation, regulatory approvals, and payor expansion. Guardant360 CDx's companion diagnostic status with Veppanu ensures a sustainable revenue tailwind tied to the drug's commercial success.

Wall Street View

With a forward P/E of -133.46x (reflecting losses), traditional valuation is irrelevant. Instead, investors are pricing in path to profitability. The raised guidance and FDA approval signal that inflection may be closer than previously expected.

Investor Takeaway

Guardant Health's Q1 results confirm it is capturing share in a market shift toward liquid biopsy screening. The 39.4% revenue growth, FDA companion diagnostic approval, and raised full-year guidance form a powerful bull case—the company is moving through an inflection point from development-stage to commercial scale. The negative operating margin is temporary; once the company achieves scale in screening diagnostics, margin expansion should be significant. For growth investors with risk tolerance, GH offers exposure to one of oncology's highest-conviction secular trends.